Inhibitory Effects of 7-Methylguanine and Its Metabolite 8-Hydroxy-7-Methylguanine on Human Poly(ADP-Ribose) Polymerase 1

[1]  V. Svedas,et al.  Molecular Mechanisms of PARP-1 Inhibitor 7-Methylguanine , 2020, International journal of molecular sciences.

[2]  T. Pan,et al.  tRNA Queuosine Modification Enzyme Modulates the Growth and Microbiome Recruitment to Breast Tumors , 2020, Cancers.

[3]  J. Giebułtowicz,et al.  Development and validation of a rapid LC-MS/MS method for determination of methylated nucleosides and nucleobases in urine. , 2019, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[4]  B. Patel,et al.  Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update. , 2019, European journal of medicinal chemistry.

[5]  Olga I Lavrik,et al.  Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins , 2019, Nucleic acids research.

[6]  A. Sapino,et al.  PARP Inhibitors in Ovarian Cancer. , 2018, Recent patents on anti-cancer drug discovery.

[7]  P. Neumann,et al.  Crystal Structure of the Human tRNA Guanine Transglycosylase Catalytic Subunit QTRT1 , 2018, Biomolecules.

[8]  R. Henning,et al.  Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders , 2018, Cardiovascular Toxicology.

[9]  S. Khodyreva,et al.  Unusual interaction of human apurinic/apyrimidinic endonuclease 1 (APE1) with abasic sites via the Schiff-base-dependent mechanism. , 2018, Biochimie.

[10]  A. A. Lagunin,et al.  Computer-aided Prediction of Biological Activity Spectra for Chemical Compounds: Opportunities and Limitations , 2018 .

[11]  S. Lipkowitz,et al.  Update on PARP Inhibitors in Breast Cancer , 2018, Current Treatment Options in Oncology.

[12]  O. Lavrik,et al.  A rapid fluorescent method for the real-time measurement of poly(ADP-ribose) polymerase 1 activity. , 2018, Analytical biochemistry.

[13]  S. Snyder,et al.  Opportunities for the repurposing of PARP inhibitors for the therapy of non‐oncological diseases , 2018, British journal of pharmacology.

[14]  V. Svedas,et al.  Structure Modeling of Human Tyrosyl-DNA Phosphodiesterase 1 and Screening for Its Inhibitors , 2017, Acta naturae.

[15]  V. Svedas,et al.  Inhibition of Poly(ADP-Ribose) Polymerase by Nucleic Acid Metabolite 7-Methylguanine , 2016, Acta naturae.

[16]  O. Lavrik,et al.  Synthesis and biological evaluation of novel tyrosyl-DNA phosphodiesterase 1 inhibitors with a benzopentathiepine moiety. , 2015, Bioorganic & medicinal chemistry.

[17]  J. Frampton.  Olaparib: A Review of Its Use as Maintenance Therapy in Patients with Ovarian Cancer , 2015, BioDrugs.

[18]  Alan Ashworth,et al.  Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. , 2015, Annual review of medicine.

[19]  R. Carabias-Martínez,et al.  Capillary electrophoresis-mass spectrometry for direct determination of urinary modified nucleosides. Evaluation of synthetic urine as a surrogate matrix for quantitative analysis. , 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[20]  N. Curtin,et al.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. , 2013, Molecular aspects of medicine.

[21]  S. Khodyreva,et al.  Disaccharide Pyrimidine Nucleosides and Their Derivatives: A Novel Group of Cell-Penetrating Inhibitors of Poly(ADP-Ribose) Polymerase 1 , 2013, Nucleosides, nucleotides & nucleic acids.

[22]  T. Oretskaya,et al.  Clustered DNA Lesions Containing 5-Formyluracil and AP Site: Repair via the BER System , 2013, PloS one.

[23]  J. Medina-Franco,et al.  Shifting from the single to the multitarget paradigm in drug discovery. , 2013, Drug discovery today.

[24]  M L Bolognesi,et al.  Polypharmacology in a single drug: multitarget drugs. , 2013, Current medicinal chemistry.

[25]  V. Svedas,et al.  Construction of a Full-Atomic Mechanistic Model of Human Apurinic/Apyrimidinic Endonuclease APE1 for Virtual Screening of Novel Inhibitors
 , 2012, Acta naturae.

[26]  Fedor N. Novikov,et al.  Lead Finder docking and virtual screening evaluation with Astex and DUD test sets , 2012, Journal of Computer-Aided Molecular Design.

[27]  Stefan Fischer,et al.  Compartmentation of NAD+‐dependent signalling , 2011, FEBS letters.

[28]  Nahum Sonenberg,et al.  Cap and cap‐binding proteins in the control of gene expression , 2011, Wiley interdisciplinary reviews. RNA.

[29]  Hiroshi Kasai,et al.  Effect of age, smoking and other lifestyle factors on urinary 7‐methylguanine and 8‐hydroxydeoxyguanosine , 2009, Cancer science.

[30]  Fedor N. Novikov,et al.  Lead finder: an approach to improve accuracy of protein-ligand docking, binding energy estimation, and virtual screening. , 2008, Journal of chemical information and modeling.

[31]  A. Ashworth,et al.  DNA repair deficiency as a therapeutic target in cancer. , 2008, Current opinion in genetics & development.

[32]  Samuel H. Wilson,et al.  Structure and Mechanism of DNA Polymerase β , 2006, Biochemistry.

[33]  H. Kasai,et al.  Simultaneous HPLC analysis of 8-hydroxydeoxyguanosine and 7-methylguanine in urine from humans and rodents. , 2004, Analytical biochemistry.

[34]  Stewart Shuman,et al.  What messenger RNA capping tells us about eukaryotic evolution , 2002, Nature Reviews Molecular Cell Biology.

[35]  J. Pouliot,et al.  Pathways for repair of topoisomerase I covalent complexes in Saccharomyces cerevisiae , 2001, Genes to cells : devoted to molecular & cellular mechanisms.

[36]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[37]  Y. Matsumoto,et al.  Excision of deoxyribose phosphate residues by DNA polymerase beta during DNA repair. , 1995, Science.

[38]  K. Hemminki,et al.  7-Methylguanine levels in DNA of smokers' and non-smokers' total white blood cells, granulocytes and lymphocytes. , 1992, Carcinogenesis.

[39]  B. Demple,et al.  Cloning and expression of APE, the cDNA encoding the major human apurinic endonuclease: definition of a family of DNA repair enzymes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[40]  B. Ames,et al.  7-Methylguanine adducts in DNA are normally present at high levels and increase on aging: analysis by HPLC with electrochemical detection. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[41]  K. Jacobson,et al.  Substrate and inhibitor specificity of tRNA-guanine ribosyltransferase. , 1984, Biochimica et biophysica acta.

[42]  B. Kaina,et al.  O6-methylguanine, but not N7-methylguanine or N3-methyladenine, induces gene mutations, sister-chromatid exchanges and chromosomal aberrations in Chinese hamster cells. , 1983, Mutation research.

[43]  P. Magee,et al.  The fate of 7[14C]-methylguanine after administration to the rat. , 1968, The Biochemical journal.

[44]  B. Weissmann,et al.  Source of urinary 8-hydroxy-7-methylguanine in man. , 1966, Biochemistry.

[45]  I. Borowitz,et al.  METHYLATED PURINES AND PYRIMIDINES. I. SYNTHESES OF 8-HYDROXY-7-METHYLGUANINE AND METHYLATION OF A 5-(BENZYLIDENEAMINO) PYRIMIDINE. , 1965, Biochemistry.

[46]  E. Fischer.  Verwandlung des Theobromins in methylierte Harnsäuren , 1895 .

[47]  M. Fuertes,et al.  Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy. , 2006, Recent patents on anti-cancer drug discovery.